Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants
Sponsor: Göteborg University
Summary
Babies born extremely preterm (before 28 weeks of pregnancy) miss most of the transfer of two long-chain fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), that normally passes from mother to baby in the last three months of pregnancy. Low levels of these fatty acids after birth have been linked to retinopathy of prematurity (ROP), an eye disease that can threaten vision, and to other complications of prematurity. In a Swedish randomized trial (Mega Donna Mega), an enteral supplement of ARA and DHA reduced severe ROP by about half. A similar supplement, NeoMega36, is now used in routine care in several European neonatal units and is being introduced in Sweden. This observational study examines whether the introduction of NeoMega36 into routine care is followed by less ROP and fewer other complications of prematurity. It compares infants born at 22+0 to 27+6 weeks of gestation who were cared for before NeoMega36 was introduced at their unit (historical period) with infants cared for after it was introduced (NeoMega period). The study has two parts: * European part: participating neonatal units report aggregated counts (number of infants and number with each outcome, by gestational week and period). No individual-level data leave the hospitals. * Swedish part: coded individual-level data are retrieved from the Swedish Neonatal Quality Register (SNQ) and the Swedish national register for ROP (SWEDROP). The study does not give, assign or change any treatment. NeoMega36 is given as part of routine clinical care according to each unit's own practice. There are no extra examinations, visits or contacts with families. The main hypothesis is that the proportion of infants with severe ROP is lower in the NeoMega period than in the historical period. Other outcomes are treated ROP, any ROP, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), death before discharge, and the combined outcomes BPD or death and NEC or death. Because this is a before-and-after comparison, differences between the periods may also reflect other changes in care over time, and the results will be interpreted with this in mind.
Official title: Multinational Observational Before-and-after Study of Clinical Outcomes After Introduction of NeoMega36 Fatty-acid Supplementation in Extremely Preterm Infants
Key Details
Gender
All
Age Range
Any - 28 Days
Study Type
OBSERVATIONAL
Enrollment
2100
Start Date
2026-06-16
Completion Date
2036-03-31
Last Updated
2026-11-18
Healthy Volunteers
No
Conditions
Interventions
Enteral arachidonic acid and docosahexaenoic acid supplement
Enteral lipid supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) in a 2:1 ratio (NeoMega36, Neobiomics, Solna, Sweden), given in routine neonatal care according to each unit's local protocol for eligibility, dose, and start and stop criteria. The supplement is not assigned, provided or changed by the study. Exposure is defined at period level as implementation of NeoMega36 in routine care at the unit.
Locations (1)
Sahlgrenska Academy, University of Gothenburg
Gothenburg, Sweden